Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

ALTERRA Post-Approval Study

NCT: NCT05378386 · ACTIVE_NOT_RECRUITING

NCT IDNCT05378386
StatusACTIVE_NOT_RECRUITING
Start Date2022-05-12
Completion2035-07
SponsorEdwards Lifesciences (INDUSTRY)
First posted
Last updated

Brief Summary

This study will monitor device performance and outcomes in subjects undergoing implantation of the Edwards SAPIEN 3 Transcatheter Pulmonary Valve System with Alterra Adaptive Prestent in the post-approval setting

Frequently Asked Questions

What is ALTERRA Post-Approval Study?

ALTERRA Post-Approval Study is a clinical trial registered under NCT05378386. Current status: ACTIVE_NOT_RECRUITING.

What is the status of NCT05378386?

The current status of NCT05378386 (ALTERRA Post-Approval Study) is: ACTIVE_NOT_RECRUITING.

When did ALTERRA Post-Approval Study start?

ALTERRA Post-Approval Study started on 2022-05-12.

Related Devices

PMA P200015Pulmonary valve prosthesis percutaneously deliveredEdwards Lifesciences, LLC

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑